RTP Mobile Logo
Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers
Released December 2018

Proceedings from a daylong symposium featuring key clinical presentations and papers in acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and ovarian cancer. Including perspectives from Drs Al B Benson III, Harold J Burstein, Don S Dizon, Howard S Hochster, Brad S Kahl, Corey J Langer, Frederick L Locke, Peter H O’Donnell, David M O’Malley, Geoffrey R Oxnard, Hope S Rugo, Guru Sonpavde, Eytan M Stein, Stacey Stein, Richard M Stone and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and ovarian cancer to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YIRMultitumor18/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Al B Benson III, MD
    Professor of Medicine
    Associate Director for Clinical Investigations
    Robert H Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, Guardant Health, Merck; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Merck Sharp & Dohme Corp, Novartis, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Infinity Pharmaceuticals Inc.

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Don S Dizon, MD
    Director, Women’s Cancers
    Founder, Sexual Health First Responders Clinic
    Lifespan Cancer Institute
    Director of Medical Oncology, Rhode Island Hospital
    Associate Professor of Medicine, Alpert Medical School of Brown University
    Providence, Rhode Island

    Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Regeneron Pharmaceuticals Inc.

    Howard S Hochster, MD
    Associate Director (Clinical Research)
    Yale Cancer Center
    Professor of Medicine
    Yale School of Medicine
    New Haven, Connecticut

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech; Data and Safety Monitoring Board/Committee: Genentech, Pfizer Inc.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements: Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company.

    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    Perelman School of Medicine
    University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Lilly, Merck, Pfizer Inc, Takeda Oncology; Consulting Agreements: Bayer HealthCare Pharmaceuticals, BeiGene, Genentech, Guardant Health, Lilly, Merck, Novocure; Contracted Research: Advantagene Inc, Inovio Pharmaceuticals Inc, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc, Incyte Corporation, Lilly, SWOG.

    Frederick L Locke, MD
    Program Co-Leader, Immunology
    Moffitt Cancer Center
    Tampa, Florida

    Advisory Committee: Gilead Sciences Inc, Kite Pharma Inc, Novartis; Consulting Agreement: Cellular Biomedicine Group Inc.

    Peter H O’Donnell, MD
    Assistant Professor, Department of Medicine
    Section of Hematology/Oncology
    Genitourinary Oncology Program
    The University of Chicago
    Chicago, Illinois

    Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP/MedImmune Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, Janssen Biotech Inc, Merck, Seattle Genetics; Expert Testimony: Temple Health, Trinity Health; Honoraria: Algeta ASA, American Medical Forum, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech, Harrison Consulting, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Kantar Health, Merck, Novartis, PAREXEL International Corporation, Quintiles, Seattle Genetics, Xcenda; Stock: Allergan Inc; Travel: Merck.

    David M O’Malley, MD
    Professor
    Director, Clinical Research, Gynecologic Oncology
    Co-Director, Gynecologic Oncology Phase I Program
    ORIEN Physician Liaison for OSUCCC – James
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Advisory Committee: Amgen Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

    Geoffrey R Oxnard, MD
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, DropWorks CEI, GRAIL Inc, Guardant Health, Ignyta Inc, Inivata, Loxo Oncology.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Eisai Inc, Genentech, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Plexxikon Inc, Roche Laboratories Inc; Paid Travel: Lilly, Mylan NV, Puma Biotechnology Inc.

    Guru Sonpavde, MD
    Bladder Cancer Director
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, EMD Serono Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme; Data and Safety Monitoring Board/Committee: Boehringer Ingelheim Pharmaceuticals Inc; Other Remunerated Activities: Author of UpToDate.

    Eytan M Stein, MD
    Hematologist and Medical Oncologist
    Assistant Attending Physician
    Leukemia Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Pfizer Inc.

    Stacey Stein, MD
    Assistant Professor of Medicine (Medical Oncology)
    Yale Cancer Center
    New Haven, Connecticut

    Advisory Committee: Eisai Inc, Genentech, Merck.

    Richard M Stone, MD
    Director, Adult Leukemia Program
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Agios Pharmaceuticals Inc, Amgen Inc, Argenx, Arog Pharmaceuticals Inc, Astellas Pharma Global Development Inc, Celator Pharmaceuticals Inc, Celgene Corporation, FUJIFILM Pharmaceuticals USA Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Juno Therapeutics, Karyopharm Therapeutics, Merck, Novartis, Orsenix, Otsuka America Pharmaceutical Inc, Pfizer Inc, Rafael Pharmaceuticals Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Novartis.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Novartis, TG Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Guardant Health, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Taiho Oncology Inc and Tesaro Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2018
    Expiration date: December 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):